Abstract
During the past decade, the arena of polymer therapeutics has acquired considerable interest and accompanied by advanced designs and chemical properties of polymer-drug conjugates. Various polymers, such as poly (ethylene glycol) (PEG), N-(2-hydroxypropyl) methacrylamide (HPMA), poly(glycolic acid) (PGA) and poly(lactide-co-glycolide) (PLGA) have been used successfully for clinical utilization from decades. These polymers are used in combination of drugs in such a manner that they target the specific tissues and thus the toxicity of drugs to other tissues is reduced. Presently, numerous polymer drug conjugates are under clinical trial for treatment of various diseases including cancer, diabetes, AIDS, rheumatoid arthritis etc. Many protein-polymer conjugates have been approved by FDA for clinical use but till date, no polymer-synthetic drug conjugate is approved by FDA, although many of them are undergoing final phase of clinical trials. This review highlights the recent advancements in the polymer-drug conjugates for treatment of various diseases and their preclinical and clinical status.
Keywords: Polymer, cancer, diabetes, conjugates, antiviral, disease.
Current Pharmaceutical Design
Title:Polymer Drug Conjugates: Recent Advancements in Various Diseases
Volume: 22 Issue: 19
Author(s): Jasbir Singh, Sapna Desai, Snehlata Yadav, Balasubramanian Narasimhan and Harmeet Kaur
Affiliation:
Keywords: Polymer, cancer, diabetes, conjugates, antiviral, disease.
Abstract: During the past decade, the arena of polymer therapeutics has acquired considerable interest and accompanied by advanced designs and chemical properties of polymer-drug conjugates. Various polymers, such as poly (ethylene glycol) (PEG), N-(2-hydroxypropyl) methacrylamide (HPMA), poly(glycolic acid) (PGA) and poly(lactide-co-glycolide) (PLGA) have been used successfully for clinical utilization from decades. These polymers are used in combination of drugs in such a manner that they target the specific tissues and thus the toxicity of drugs to other tissues is reduced. Presently, numerous polymer drug conjugates are under clinical trial for treatment of various diseases including cancer, diabetes, AIDS, rheumatoid arthritis etc. Many protein-polymer conjugates have been approved by FDA for clinical use but till date, no polymer-synthetic drug conjugate is approved by FDA, although many of them are undergoing final phase of clinical trials. This review highlights the recent advancements in the polymer-drug conjugates for treatment of various diseases and their preclinical and clinical status.
Export Options
About this article
Cite this article as:
Singh Jasbir, Desai Sapna, Yadav Snehlata, Narasimhan Balasubramanian and Kaur Harmeet, Polymer Drug Conjugates: Recent Advancements in Various Diseases, Current Pharmaceutical Design 2016; 22 (19) . https://dx.doi.org/10.2174/1381612822666160217125515
DOI https://dx.doi.org/10.2174/1381612822666160217125515 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sole Anti-inflammatory Immunomodulators: Innovative Drugs to Prevent and Treat Autoimmune Diseases and Proteopathies
Current Chinese Science Analytical Methodologies for Determination of Hydroxychloroquine and its Metabolites in Pharmaceutical, Biological and Environmental Samples
Current Pharmaceutical Analysis The Two Faces of Interleukin-17A in Atherosclerosis
Current Drug Targets Understanding and Applying Personalized Therapeutics at Systems Level:Role for Translational Bioinformatics
Current Pharmacogenomics and Personalized Medicine Are B Cells a Potential Target for Therapeutic Intervention in the Classical T Cell-Mediated Autoimmune Disease Type 1 Diabetes?
Inflammation & Allergy - Drug Targets (Discontinued) Protein Kinase A (PKA) - A Potential Target for Therapeutic Intervention of Dysfunctional Immune Cells
Current Drug Targets Coronary Microvascular Dysfunction and Heart Failure with Preserved Ejection Fraction - implications for Chronic Inflammatory Mechanisms
Current Cardiology Reviews Ruthenium as an Effective Nitric Oxide Scavenger
Current Topics in Medicinal Chemistry Complement and Microglia in the Neuropathogenesis of HIV Infection: Pro- and Anti-Inflammatory Aspects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Cross-over of Anticancer Agents with Osteoclast Activities
Current Cancer Therapy Reviews Polyglandular Autoimmune Syndromes
Current Immunology Reviews (Discontinued) Purine Nucleoside Phosphorylase: A Potential Target for the Development of Drugs to Treat T-Cell- and Apicomplexan Parasite-Mediated Diseases
Current Drug Targets Prediction of Citrullination Sites on the Basis of mRMR Method and SNN
Combinatorial Chemistry & High Throughput Screening Physicochemical and Biological Aspects of Curcumin: A Review
The Natural Products Journal Quantitative Structure-Activity Relationship Studies: Understanding the Mechanism of Tyrosine Kinase Inhibition
Current Enzyme Inhibition Application of Agents Against Interferon-Gamma-Dependent Chemokines in Immunotherapy
Letters in Drug Design & Discovery Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics The Proteasome in Health and Disease
Current Pharmaceutical Design The Molecular Control of Antigenic Variation in Trypanosoma brucei
Current Molecular Medicine FDG-PET/CT in Rheumatoid Arthritis: A Review
Current Molecular Imaging (Discontinued)